KCI Biotech (SUZHOU) Inc. (KCI) and Jiangsu KMQ biotech Inc. (KMQ) which is a wholly-owned subsidiary of KCI are preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases, urinary diseases, neuron diseases and oncology by using small (mice, rats, etc.) and large (non human primates, dogs, rabbits, guinea pig etc.) animal disease models. The core competency of KCI&KMQ stems from our pioneering work and expertise in developing and running specialized animal disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible. We also conduct adjacency studies in PK/PD, preliminary toxicology, medical image, translational medicine and pathology.
KCI locates in Suzhou industry park. We have 7200sq.ft. of SPF animal facility for about 7000 mice and 5000 rats studies at same time; 5400sq.ft. of experimental laboratories for pathology, cell biology, molecular biology, formulation and other functional laboratories. KMQ, our large animal facility locates in Haimen (Linjiang), is about 30,000sq.ft. for about 500 guinea pigs, 300 rabbits, 200 dogs, 200 monkeys studies at same time; 18000sq.ft. of experimental laboratories for image facility including MRI, CT, X-ray, B-Ultrasound, operation rooms, cell biology, molecular biology, formulation and other functional laboratories.